Possibly. Though, since the IC50 value for FTO inhibition is hundreds of times lower than topo2, Zan will be binding to FTO molecules long before it binds to topo2.
Using Zantrene as an anthracene to treat cancer is like using your forehead to hit a nail into wood. You can do it, but you're probably better off getting a hammer (FTO inhibition).
Something for holders to mull over - there is as much clinical validation data for topo2 as there is for FTO. Historical researchers just assumed it was topo2 because FTO wasn't known at the time. My bet is FTO.
- Forums
- ASX - By Stock
- RAC
- Ann: Impressive Bisantrene Phase 2 AML Clinical Results
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-104
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.77 |
Change
0.015(0.86%) |
Mkt cap ! $300.6M |
Open | High | Low | Value | Volume |
$1.82 | $1.82 | $1.77 | $91.78K | 51.30K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 31147 | $1.73 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.80 | 8318 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 31147 | 1.730 |
2 | 10877 | 1.710 |
3 | 45398 | 1.700 |
1 | 4450 | 1.690 |
1 | 2500 | 1.680 |
Price($) | Vol. | No. |
---|---|---|
1.795 | 8318 | 1 |
1.800 | 40724 | 3 |
1.825 | 548 | 1 |
1.830 | 5894 | 2 |
1.840 | 10500 | 2 |
Last trade - 15.59pm 10/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online